<DOC>
	<DOCNO>NCT02712008</DOCNO>
	<brief_summary>The primary objective study compare efficacy intravitreal ( IVT ) -administered REGN910-3 compare intravitreal aflibercept injection ( IAI ) improve best correct visual acuity ( BCVA ) patient diabetic macular edema ( DME ) .</brief_summary>
	<brief_title>Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 Fixed comBination therapY : Evaluation Treatment Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>KEY 1 . Men woman â‰¥18 year age type 1 type 2 diabetes mellitus clinically significant DME central involvement study eye 2 . BCVA ETDRS letter score 73 24 ( Snellen equivalent 20/40 20/320 ) study eye 3 . Willing able comply clinic visit studyrelated procedure 4 . Provide sign informed consent KEY 1 . Evidence macular edema due cause diabetes mellitus either eye 2 . IVT antiVEGF study eye within 12 week screen visit 3 . Panretinal laser photocoagulation macular laser photocoagulation study eye within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>